Kazia’s CEO, Dr James Garner, was recently interviewed by Tom Piotrowski for CommSec’s Executive Series.
In the interview, Dr Garner discusses:
- Kazia’s recent $4mn capital raising, including the reasons behind the timing of the raise and why it was important to have the raise supported by specialist institutional investors.
- The Company’s recent efficacy data from its Cantrixil trial in ovarian cancer and the significance of treating patients in the later stages of the disease.
- The upcoming release of first efficacy data from Kazia’s phase II study of GDC-0084 in glioblastoma, expected in November.
- Kazia’s recent win in the inaugural ANZLF Trans-Tasman Innovation + Growth Awards.
For more information on Kazia’s recent capital raise, read the ASX Announcement here
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.